

Special Issue

10th Anniversary of Antibiotics –Recent Advances in Bacteriophage Therapy

Message from the Guest Editor

The *Antibiotics* journal was founded in 2012 and, during the past 10 years, has launched more than 100 Special Issues and published more than 1500 papers. The journal covers all aspects of antibiotic discovery, use and preservation. The year 2021 marks the 10th anniversary of *Antibiotics*, which we are excited to celebrate with a Special Issue. This Special Issue welcomes both research and review papers on the most recent and innovative developments in phage therapy bacteriophages. We hope that the Special Issue can further encourage and promote the scientific contributions of the researchers in this field, highlighting the advances in phage therapy in both clinical and nonclinical areas, namely:

- Phage therapy against multidrug-resistant bacteria, intracellular bacteria, bacteria capable of forming biofilms, and bacteria involved in chronic infections;
- The impact of phage use on the environment;
- The effects of environmental factors on phage viability;
- The functional stabilization/preservation of phage particles;
- Phage administration routes, phage concentrations, and moments of treatment;
- Phage specificity to target bacteria

Guest Editor

Prof. Dr. Adelaide Almeida

Departamento de Biologia, CESAM - Centro de Estudos do Ambiente e do Mar, Campus Universitário de Santiago, Universidade de Aveiro, 3810-193 Aveiro, Portugal

Deadline for manuscript submissions

closed (31 December 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/78779

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)